Clinical trial
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib…
NCT00404066 · George Albert Fisher, Other · Completed
Key facts
| NCT number | NCT00404066 |
|---|---|
| Title | Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer |
| Official title | Phase II Neoadjuvant Chemotherapy Trial in Clinical Stage II/III Her2Neu Positive Breast Cancer With Sequential AC -> Docetaxel With Concurrent Dual EGFR Kinase Blockade by GW572016 (Lapatinib) Followed by 1 Year Adjuvant Trastuzumab |
| Lead sponsor | George Albert Fisher, Other |
| Collaborators | GlaxoSmithKline Industry Sanofi |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Lapatinib, Doxorubicin, Cyclophosphamide, Docetaxel, Pegfilgrastim, Filgrastim, Dexamethasone, Trastuzumab |
| Enrollment | 21 |
| Start date | Oct 1, 2006 |
| Primary completion | Dec 1, 2010 |
| Completion | Mar 1, 2011 |
| First posted | Nov 27, 2006 |
| Last update posted | Dec 22, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: